Global Duchenne Muscular Dystrophy Drugs Market - Industry Analysis Size Share Growth Trends and Forecast 2022 - 2030

Global Duchenne Muscular Dystrophy Drugs Market - Industry Analysis Size Share Growth Trends and Forecast 2022 - 2030

  • SKU :
    SAC2059176
  • Published Date :
    June 1, 2022
  • Number of Pages :
    350.0

Product Description

The Duchenne Muscular Dystrophy Drugs market was valued at US$ xx in 2021, prior to COVID-19. Whereas post-COVID-19 scenario,  the market for Duchenne Muscular Dystrophy Drugs is projected to grow from US$ xx million in 2021, and is projected to reach xx by 2030, at a CAGR of xx% during the forecast period. Projected and forecast revenue values are in constant U.S. dollars, unadjusted for inflation. Product values are estimated based on manufacturers' revenue.

The report offers detailed coverage of Duchenne Muscular Dystrophy Drugs industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Duchenne Muscular Dystrophy Drugs by geography. The report splits the market size, by volume and value, on the basis of application type and geography.

In addition to this data, the report provides insight into drivers of market demand and strategies of suppliers. Key players are profiled, and their market shares in the global Duchenne Muscular Dystrophy Drugs market are discussed.

The market is segmented by types: 
    Development & Drug Target
    Mechanism of Action (MoA)
    Route of Administration (RoA)
    Molecule Type

It can be also divided by applications:
    Hospitals and Clinics
    Medical Laboratories
    Others

And this report covers the historical situation, present status and the future prospects of the global Duchenne Muscular Dystrophy Drugs market for 2021-2030. In this report, we analyze global market from 5 geographies: Asia-Pacific, Europe, North America, Middle East & Africa, South America.

Finally, the report provides detailed profile and data information analysis of leading company.
    Akashi Therapeutics Inc
    Antisense Therapeutics Ltd
    Beech Tree Labs Inc
    Biogen Inc
    Bioleaders Corp
    BioMarin Pharmaceutical Inc
    Biophytis SAS
    Capricor Therapeutics Inc
    Catabasis Pharmaceuticals Inc
    CRISPR Therapeutics
    Cumberland Pharmaceuticals Inc
    Daiichi Sankyo Co Ltd
    Debiopharm International SA
    Editas Medicine Inc
    Eloxx Pharmaceuticals Inc
    F. Hoffmann-La Roche Ltd
    FibroGen Inc
    Fulcrum Therapeutics Inc
    Galapagos NV
    Genethon SA
    GTx Inc
    Santhera Pharmaceuticals Holding AG
    Sarepta Therapeutics Inc
    SOM Biotech SL
    Strykagen Corp
    Summit Therapeutics Plc
    Taiho Pharmaceutical Co Ltd
    Teijin Pharma Ltd
    WAVE Life Sciences Ltd

Report Includes:
- xx data tables and xx additional tables
- An overview of global Duchenne Muscular Dystrophy Drugs market
- An detailed key players analysis across regions
- Analyses of global market trends, with historical data, estimates for 2022 and projections of compound annual growth rates (CAGRs) through 2030
- Insights into regulatory and environmental developments
- Information on the supply and demand scenario and evaluation of technological and investment opportunities in the Duchenne Muscular Dystrophy Drugs market
- Profiles of major players in the industry, including     Akashi Therapeutics Inc,     Antisense Therapeutics Ltd,     Beech Tree Labs Inc,     Biogen Inc,     Bioleaders Corp.....

Research objectives
    To study and analyze the global Duchenne Muscular Dystrophy Drugs consumption (value & volume) by key regions/countries, product type and application, history data from 2018 to 2021, and Forecast to 2030.
    To understand the structure of Duchenne Muscular Dystrophy Drugs market by identifying its various subsegments.
    Focuses on the key global Duchenne Muscular Dystrophy Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, Porter's five forces analysis, SWOT analysis and development plans in next few years.
    To analyze the Duchenne Muscular Dystrophy Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
    To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
    To project the consumption of Duchenne Muscular Dystrophy Drugs submarkets, with respect to key regions (along with their respective key countries).
    To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
    To strategically profile the key players and comprehensively analyze their growth strategies.

Table of Content 

Table of Contents

Global Duchenne Muscular Dystrophy Drugs Market Report 2022, Forecast to 2030

1 Scope of the Study
    1.1 Duchenne Muscular Dystrophy Drugs Introduction
    1.2 Research Programs
    1.3 Analysis of Macroeconomic Indicators
    1.4 Years Considered
    1.5 Methodology
    1.6 Data Source
    1.7 Research Objectives

2 Duchenne Muscular Dystrophy Drugs Industry Overview
    2.1 Global Duchenne Muscular Dystrophy Drugs Market Size (Million USD) Comparison by Regions (2022-2030)
        2.1.1 Duchenne Muscular Dystrophy Drugs Global Import Market Analysis
        2.1.2 Duchenne Muscular Dystrophy Drugs Global Export Market Analysis
        2.1.3 Duchenne Muscular Dystrophy Drugs Global Main Region Market Analysis
    2.2 Market Analysis by Type
        2.2.1 Development & Drug Target
        2.2.2 Mechanism of Action (MoA)
        2.2.3 Route of Administration (RoA)
        2.2.4 Molecule Type
    2.3 Market Analysis by Application
        2.3.1 Hospitals and Clinics
        2.3.2 Medical Laboratories
        2.3.3 Others
    2.4 Global Duchenne Muscular Dystrophy Drugs Revenue, Sales and Market Share by Manufacturer
        2.4.1 Global Duchenne Muscular Dystrophy Drugs Sales and Market Share by Manufacturer (2018-2021)
        2.4.2 Global Duchenne Muscular Dystrophy Drugs Revenue and Market Share by Manufacturer (2018-2021)
        2.4.3 Global Duchenne Muscular Dystrophy Drugs Industry Concentration Ratio (CR5 and HHI)
        2.4.4 Top 5 Duchenne Muscular Dystrophy Drugs Manufacturer Market Share
        2.4.5 Top 10 Duchenne Muscular Dystrophy Drugs Manufacturer Market Share
        2.4.6 Date of Key Manufacturers Enter into Duchenne Muscular Dystrophy Drugs Market
        2.4.7 Key Manufacturers Duchenne Muscular Dystrophy Drugs Product Offered
        2.4.8 Mergers & Acquisitions Planning
    2.5 Duchenne Muscular Dystrophy Drugs Historical Development Overview
    2.6 Market Dynamics
        2.6.1 Market Opportunities
        2.6.2 Market Risk
        2.6.3 Market Driving Force
        2.6.4 Porter's Five Forces Analysis
    2.7 Coronavirus Disease 2019 (Covid-19): Duchenne Muscular Dystrophy Drugs Industry Impact
        2.7.1 How the Covid-19 is Affecting the Duchenne Muscular Dystrophy Drugs Industry
        2.7.2 Duchenne Muscular Dystrophy Drugs Business Impact Assessment - Covid-19
        2.7.3 Market Trends and Duchenne Muscular Dystrophy Drugs Potential Opportunities in the COVID-19 Landscape
        2.7.4 Measures / Proposal against Covid-19

3 Upstream and Downstream Market Analysis
    3.1 Upstream Analysis
        3.1.1 Macro Analysis of Upstream Markets
        3.1.2 Key Players in Upstream Markets
        3.1.3 Upstream Market Trend Analysis
        3.1.4 Duchenne Muscular Dystrophy Drugs Manufacturing Cost Analysis
    3.2 Downstream Market Analysis
        3.2.1 Macro Analysis of Down Markets
        3.2.2 Key Players in Down Markets
        3.2.3 Downstream Market Trend Analysis
        3.2.4 Sales Channel, Distributors, Traders and Dealers

4 Global Duchenne Muscular Dystrophy Drugs Market Size Categorized by Regions
    4.1 Global Duchenne Muscular Dystrophy Drugs Revenue, Sales and Market Share by Regions
        4.1.1 Global Duchenne Muscular Dystrophy Drugs Sales and Market Share by Regions (2018-2021)
        4.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue and Market Share by Regions (2018-2021)
    4.2 Europe Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2018-2021)
    4.3 APAC Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2018-2021)
    4.4 North America Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2018-2021)
    4.5 South America Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2018-2021)
    4.6 Middle East & Africa Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2018-2021)

5 Europe Duchenne Muscular Dystrophy Drugs Market Size Categorized by Countries
    5.1 Europe Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Countries
        5.1.1 Europe Duchenne Muscular Dystrophy Drugs Sales by Countries (2018-2021)
        5.1.2 Europe Duchenne Muscular Dystrophy Drugs Revenue by Countries (2018-2021)
        5.1.3 Germany Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2018-2021)
        5.1.4 UK Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2018-2021)
        5.1.5 France Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2018-2021)
        5.1.6 Russia Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2018-2021)
        5.1.7 Italy Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2018-2021)
        5.1.8 Spain Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2018-2021)
    5.2 Europe Duchenne Muscular Dystrophy Drugs Revenue (Value) by Manufacturers (2018-2021)
    5.3 Europe Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Type (2018-2021)
        5.3.1 Europe Duchenne Muscular Dystrophy Drugs Sales Market Share by Type (2018-2021)
        5.3.2 Europe Duchenne Muscular Dystrophy Drugs Revenue and Revenue Share by Type (2018-2021)
    5.4 Europe Duchenne Muscular Dystrophy Drugs Sales Market Share by Application (2018-2021)

6 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size Categorized by Countries
    6.1 Asia-Pacific Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Countries
        6.1.1 Asia-Pacific Duchenne Muscular Dystrophy Drugs Sales by Countries (2018-2021)
        6.1.2 Asia-Pacific Duchenne Muscular Dystrophy Drugs Revenue by Countries (2018-2021)
        6.1.3 China Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2018-2021)
        6.1.4 Japan Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2018-2021)
        6.1.5 Korea Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2018-2021)
        6.1.6 India Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2018-2021)
        6.1.7 Southeast Asia Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2018-2021)
        6.1.8 Australia Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2018-2021)
    6.2 Asia-Pacific Duchenne Muscular Dystrophy Drugs Sales and Revenue (Value) by Manufacturers (2018-2021)
    6.3 Asia-Pacific Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Type (2018-2021)
        6.3.1 Asia-Pacific Duchenne Muscular Dystrophy Drugs Sales Market Share by Type (2018-2021)
        6.3.2 Asia-Pacific Duchenne Muscular Dystrophy Drugs Revenue and Revenue Share by Type (2018-2021)
    6.4 Asia-Pacific Duchenne Muscular Dystrophy Drugs Sales and Market Share by Application (2018-2021)

7 North America Duchenne Muscular Dystrophy Drugs Market Size Categorized by Countries
    7.1 North America Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Countries
        7.1.1 North America Duchenne Muscular Dystrophy Drugs Sales by Countries (2018-2021)
        7.1.2 North America Duchenne Muscular Dystrophy Drugs Revenue by Countries (2018-2021)
        7.1.3 United States Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2018-2021)
        7.1.4 Canada Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2018-2021)
        7.1.5 Mexico Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2018-2021)
    7.2 North America Duchenne Muscular Dystrophy Drugs Revenue (Value) by Manufacturers (2018-2021)
    7.3 North America Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Type (2018-2021)
        7.3.1 North America Duchenne Muscular Dystrophy Drugs Sales Market Share by Type (2018-2021)
        7.3.2 North America Duchenne Muscular Dystrophy Drugs Revenue and Revenue Share by Type (2018-2021)
    7.4 North America Duchenne Muscular Dystrophy Drugs Sales Market Share by Application (2018-2021)

8 South America Duchenne Muscular Dystrophy Drugs Market Size Categorized by Countries
    8.1 South America Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Countries
        8.1.1 South America Duchenne Muscular Dystrophy Drugs Sales by Countries (2018-2021)
        8.1.2 South America Duchenne Muscular Dystrophy Drugs Revenue by Countries (2018-2021)
        8.1.3 Brazil Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2018-2021)
    8.2 South America Duchenne Muscular Dystrophy Drugs Revenue (Value) by Manufacturers (2018-2021)
    8.3 South America Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Type (2018-2021)
        8.3.1 South America Duchenne Muscular Dystrophy Drugs Sales Market Share by Type (2018-2021)
        8.3.2 South America Duchenne Muscular Dystrophy Drugs Revenue and Revenue Share by Type (2018-2021)
    8.4 South America Duchenne Muscular Dystrophy Drugs Sales Market Share by Application (2018-2021)

9 Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Size Categorized by Countries
    9.1 Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Countries
        9.1.1 Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales by Countries (2018-2021)
        9.1.2 Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue by Countries (2018-2021)
        9.1.3 GCC Countries Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2018-2021)
        9.1.4 Turkey Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2018-2021)
        9.1.5 Egypt Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2018-2021)
        9.1.6 South Africa Duchenne Muscular Dystrophy Drugs Sales and Growth Rate (2018-2021)
    9.2 Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue (Value) by Manufacturers (2018-2021)
    9.3 Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales, Revenue and Market Share by Type
        9.3.1 Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales Market Share by Type (2018-2021)
        9.3.2 Middle East and Africa Duchenne Muscular Dystrophy Drugs Revenue and Revenue Share by Type (2018-2021)
    9.4 Middle East and Africa Duchenne Muscular Dystrophy Drugs Sales Market Share by Application (2018-2021)

10 Global Duchenne Muscular Dystrophy Drugs Market Segment by Type
    10.1 Global Duchenne Muscular Dystrophy Drugs Revenue, Sales and Market Share by Type (2018-2021)
        10.1.1 Global Duchenne Muscular Dystrophy Drugs Sales and Market Share by Type (2018-2021)
        10.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue and Market Share by Type (2018-2021)
    10.2 Development & Drug Target Sales Growth Rate and Price
        10.2.1 Global Development & Drug Target Sales Growth Rate (2018-2021)
        10.2.2 Global Development & Drug Target Price (2018-2021)
    10.3 Mechanism of Action (MoA) Sales Growth Rate and Price
        10.3.1 Global Mechanism of Action (MoA) Sales Growth Rate (2018-2021)
        10.3.2 Global Mechanism of Action (MoA) Price (2018-2021)
    10.4 Route of Administration (RoA) Sales Growth Rate and Price
        10.4.1 Global Route of Administration (RoA) Sales Growth Rate (2018-2021)
        10.4.2 Global Route of Administration (RoA) Price (2018-2021)
    10.5 Molecule Type Sales Growth Rate and Price
        10.5.1 Global Molecule Type Sales Growth Rate (2018-2021)
        10.5.2 Global Molecule Type Price (2018-2021)

11 Global Duchenne Muscular Dystrophy Drugs Market Segment by Application
    11.1 Global Duchenne Muscular Dystrophy DrugsSales Market Share by Application (2018-2021)
    11.2 Hospitals and Clinics Sales Growth Rate (2018-2021)
    11.3 Medical Laboratories Sales Growth Rate (2018-2021)
    11.4 Others Sales Growth Rate (2018-2021)

12 Market Forecast for Duchenne Muscular Dystrophy Drugs
    12.1 Global Duchenne Muscular Dystrophy Drugs Revenue, Sales and Growth Rate (2022-2030)
    12.2 Duchenne Muscular Dystrophy Drugs Market Forecast by Regions (2022-2030)
        12.2.1 Europe Duchenne Muscular Dystrophy Drugs Market Forecast (2022-2030)
        12.2.2 APAC Duchenne Muscular Dystrophy Drugs Market Forecast (2022-2030)
        12.2.3 North America Duchenne Muscular Dystrophy Drugs Market Forecast (2022-2030)
        12.2.4 South America Duchenne Muscular Dystrophy Drugs Market Forecast (2022-2030)
        12.2.5 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Forecast (2022-2030)
    12.3 Duchenne Muscular Dystrophy Drugs Market Forecast by Type (2022-2030)
        12.3.1 Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Type (2022-2030)
        12.3.2 Global Duchenne Muscular Dystrophy Drugs Market Share Forecast by Type (2022-2030)
    12.4 Duchenne Muscular Dystrophy Drugs Market Forecast by Application (2022-2030)
        12.4.1 Global Duchenne Muscular Dystrophy Drugs Sales Forecast by Application (2022-2030)
        12.4.2 Global Duchenne Muscular Dystrophy Drugs Market Share Forecast by Application (2022-2030)

13 Analysis of Duchenne Muscular Dystrophy Drugs Industry Key Manufacturers
    13.1 Akashi Therapeutics Inc
        13.1.1 Company Details
        13.1.2 Product Information
        13.1.3 Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2018-2021)
        13.1.4 Main Business Overview
        13.1.5 Akashi Therapeutics Inc News
    13.2 Antisense Therapeutics Ltd
        13.2.1 Company Details
        13.2.2 Product Information
        13.2.3 Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2018-2021)
        13.2.4 Main Business Overview
        13.2.5 Antisense Therapeutics Ltd News
    13.3 Beech Tree Labs Inc
        13.3.1 Company Details
        13.3.2 Product Information
        13.3.3 Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2018-2021)
        13.3.4 Main Business Overview
        13.3.5 Beech Tree Labs Inc News
    13.4 Biogen Inc
        13.4.1 Company Details
        13.4.2 Product Information
        13.4.3 Biogen Inc Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2018-2021)
        13.4.4 Main Business Overview
        13.4.5 Biogen Inc News
    13.5 Bioleaders Corp
        13.5.1 Company Details
        13.5.2 Product Information
        13.5.3 Bioleaders Corp Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2018-2021)
        13.5.4 Main Business Overview
        13.5.5 Bioleaders Corp News
    13.6 BioMarin Pharmaceutical Inc
        13.6.1 Company Details
        13.6.2 Product Information
        13.6.3 BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2018-2021)
        13.6.4 Main Business Overview
        13.6.5 BioMarin Pharmaceutical Inc News
    13.7 Biophytis SAS
        13.7.1 Company Details
        13.7.2 Product Information
        13.7.3 Biophytis SAS Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2018-2021)
        13.7.4 Main Business Overview
        13.7.5 Biophytis SAS News
    13.8 Capricor Therapeutics Inc
        13.8.1 Company Details
        13.8.2 Product Information
        13.8.3 Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2018-2021)
        13.8.4 Main Business Overview
        13.8.5 Capricor Therapeutics Inc News
    13.9 Catabasis Pharmaceuticals Inc
        13.9.1 Company Details
        13.9.2 Product Information
        13.9.3 Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2018-2021)
        13.9.4 Main Business Overview
        13.9.5 Catabasis Pharmaceuticals Inc News
    13.10 CRISPR Therapeutics
        13.10.1 Company Details
        13.10.2 Product Information
        13.10.3 CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2018-2021)
        13.10.4 Main Business Overview
        13.10.5 CRISPR Therapeutics News
    13.11 Cumberland Pharmaceuticals Inc
        13.11.1 Company Details
        13.11.2 Product Information
        13.11.3 Cumberland Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2018-2021)
        13.11.4 Main Business Overview
        13.11.5 Cumberland Pharmaceuticals Inc News
    13.12 Daiichi Sankyo Co Ltd
        13.12.1 Company Details
        13.12.2 Product Information
        13.12.3 Daiichi Sankyo Co Ltd Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2018-2021)
        13.12.4 Main Business Overview
        13.12.5 Daiichi Sankyo Co Ltd News
    13.13 Debiopharm International SA
        13.13.1 Company Details
        13.13.2 Product Information
        13.13.3 Debiopharm International SA Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2018-2021)
        13.13.4 Main Business Overview
        13.13.5 Debiopharm International SA News
    13.14 Editas Medicine Inc
        13.14.1 Company Details
        13.14.2 Product Information
        13.14.3 Editas Medicine Inc Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2018-2021)
        13.14.4 Main Business Overview
        13.14.5 Editas Medicine Inc News
    13.15 Eloxx Pharmaceuticals Inc
        13.15.1 Company Details
        13.15.2 Product Information
        13.15.3 Eloxx Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2018-2021)
        13.15.4 Main Business Overview
        13.15.5 Eloxx Pharmaceuticals Inc News
    13.16 F. Hoffmann-La Roche Ltd
        13.16.1 Company Details
        13.16.2 Product Information
        13.16.3 F. Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2018-2021)
        13.16.4 Main Business Overview
        13.16.5 F. Hoffmann-La Roche Ltd News
    13.17 FibroGen Inc
        13.17.1 Company Details
        13.17.2 Product Information
        13.17.3 FibroGen Inc Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2018-2021)
        13.17.4 Main Business Overview
        13.17.5 FibroGen Inc News
    13.18 Fulcrum Therapeutics Inc
        13.18.1 Company Details
        13.18.2 Product Information
        13.18.3 Fulcrum Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2018-2021)
        13.18.4 Main Business Overview
        13.18.5 Fulcrum Therapeutics Inc News
    13.19 Galapagos NV
        13.19.1 Company Details
        13.19.2 Product Information
        13.19.3 Galapagos NV Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2018-2021)
        13.19.4 Main Business Overview
        13.19.5 Galapagos NV News
    13.20 Genethon SA
        13.20.1 Company Details
        13.20.2 Product Information
        13.20.3 Genethon SA Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2018-2021)
        13.20.4 Main Business Overview
        13.20.5 Genethon SA News
    13.21 GTx Inc
        13.21.1 Company Details
        13.21.2 Product Information
        13.21.3 GTx Inc Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2018-2021)
        13.21.4 Main Business Overview
        13.21.5 GTx Inc News
    13.22 Santhera Pharmaceuticals Holding AG
        13.22.1 Company Details
        13.22.2 Product Information
        13.22.3 Santhera Pharmaceuticals Holding AG Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2018-2021)
        13.22.4 Main Business Overview
        13.22.5 Santhera Pharmaceuticals Holding AG News
    13.23 Sarepta Therapeutics Inc
        13.23.1 Company Details
        13.23.2 Product Information
        13.23.3 Sarepta Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2018-2021)
        13.23.4 Main Business Overview
        13.23.5 Sarepta Therapeutics Inc News
    13.24 SOM Biotech SL
        13.24.1 Company Details
        13.24.2 Product Information
        13.24.3 SOM Biotech SL Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2018-2021)
        13.24.4 Main Business Overview
        13.24.5 SOM Biotech SL News
    13.25 Strykagen Corp
        13.25.1 Company Details
        13.25.2 Product Information
        13.25.3 Strykagen Corp Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2018-2021)
        13.25.4 Main Business Overview
        13.25.5 Strykagen Corp News
    13.26 Summit Therapeutics Plc
        13.26.1 Company Details
        13.26.2 Product Information
        13.26.3 Summit Therapeutics Plc Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2018-2021)
        13.26.4 Main Business Overview
        13.26.5 Summit Therapeutics Plc News
    13.27 Taiho Pharmaceutical Co Ltd
        13.27.1 Company Details
        13.27.2 Product Information
        13.27.3 Taiho Pharmaceutical Co Ltd Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2018-2021)
        13.27.4 Main Business Overview
        13.27.5 Taiho Pharmaceutical Co Ltd News
    13.28 Teijin Pharma Ltd
        13.28.1 Company Details
        13.28.2 Product Information
        13.28.3 Teijin Pharma Ltd Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2018-2021)
        13.28.4 Main Business Overview
        13.28.5  News
    13.29 WAVE Life Sciences Ltd
        13.29.1 Company Details
        13.29.2 Product Information
        13.29.3 WAVE Life Sciences Ltd Duchenne Muscular Dystrophy Drugs Production, Price, Cost, Gross Margin, and Revenue (2018-2021)
        13.29.4 Main Business Overview
        13.29.5 WAVE Life Sciences Ltd News

14 Research Findings and Conclusion

15 Appendix

Search results for Pharmaceutical Industry

Select License Type

get a sample
Ask For Customization
Get a quote
Speak to Analyst
Buy Now

Robotics & Automation

Agriculture

Food and Beverages

Top Rated Products